Yellow fever haemagglutination-inhibiting, neutralising and IgM antibodies in vaccinated and unvaccinated residents of Ibadan, Nigeria
- PMID: 2208973
- DOI: 10.1016/0147-9571(90)90521-t
Yellow fever haemagglutination-inhibiting, neutralising and IgM antibodies in vaccinated and unvaccinated residents of Ibadan, Nigeria
Abstract
A survey for yellow fever virus haemagglutination inhibiting (HI) and neutralising (N) and IgM antibodies was carried out in unvaccinated people in Ibadan and in those immunised with the yellow fever 17-D vaccine. A total of 207 people were tested for HI antibody to yellow fever and two other flaviviruses namely: Wesselsbron and Uganda S. viruses. Prevalence of HI antibody to each flavivirus antigen was as follows: Yellow fever 26%, Wesselsbron 18% and Uganda S 33%. Of the 207 people, 37 (18%) had yellow fever N antibody. There was a higher prevalence of N antibody to yellow fever virus in adults than children. Twenty-one people vaccinated with 17-D yellow fever vaccine donated post-vaccination sera; 10 (48%) had no prevaccination HI antibody, 7 (33%) had HI antibody to one flavivirus and 4 (19%) to two or more flaviviruses. Ninety percent of seronegative people and all those with prevaccination flavivirus antibodies developed HI or N antibody, following vaccination. A total of 58 unvaccinated people were tested for yellow fever IgM antibody by an enzyme linked immunosorbent assay, 2 (3%) were positive; suggesting that active yellow fever transmission was in progress at the time of survey.
Similar articles
-
1987 yellow fever epidemics in Oyo State, Nigeria: a survey for yellow fever virus haemagglutination inhibiting antibody in residents of two communities before and after the epidemics.Virologie. 1988 Oct-Dec;39(4):261-6. Virologie. 1988. PMID: 2851207
-
Preliminary studies on the use of solid-phase immunosorbent techniques for the rapid detection of Wesselsbron virus (WSLV) IgM by haemagglutination-inhibition.Comp Immunol Microbiol Infect Dis. 1999 Jan;22(1):71-9. doi: 10.1016/s0147-9571(98)00003-4. Comp Immunol Microbiol Infect Dis. 1999. PMID: 10099030
-
Limitations of the complement-fixation test for distinguishing naturally acquired from vaccine-induced yellow fever infection in flavivirus-hyperendemic areas.Am J Trop Med Hyg. 1980 Jul;29(4):624-34. doi: 10.4269/ajtmh.1980.29.624. Am J Trop Med Hyg. 1980. PMID: 7406113
-
[The risk of yellow fever in travellers].Ned Tijdschr Geneeskd. 2006 Aug 19;150(33):1815-20. Ned Tijdschr Geneeskd. 2006. PMID: 16967591 Review. Dutch.
-
Yellow Fever at the Havanna, Its Nature and Treatment.Br Foreign Med Chir Rev. 1868 Apr;41(82):358-364. Br Foreign Med Chir Rev. 1868. PMID: 30163312 Free PMC article. Review. No abstract available.
Cited by
-
Yellow Fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data.PLoS Med. 2014 May 6;11(5):e1001638. doi: 10.1371/journal.pmed.1001638. eCollection 2014 May. PLoS Med. 2014. PMID: 24800812 Free PMC article.
-
The effect of climate change on yellow fever disease burden in Africa.Elife. 2020 Jul 28;9:e55619. doi: 10.7554/eLife.55619. Elife. 2020. PMID: 32718436 Free PMC article.
-
The global burden of yellow fever.Elife. 2021 Mar 16;10:e64670. doi: 10.7554/eLife.64670. Elife. 2021. PMID: 33722340 Free PMC article.
-
Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years.Am J Trop Med Hyg. 2013 Sep;89(3):434-44. doi: 10.4269/ajtmh.13-0264. Am J Trop Med Hyg. 2013. PMID: 24006295 Free PMC article.
-
Burden is in the eye of the beholder: Sensitivity of yellow fever disease burden estimates to modeling assumptions.Sci Adv. 2021 Oct 15;7(42):eabg5033. doi: 10.1126/sciadv.abg5033. Epub 2021 Oct 13. Sci Adv. 2021. PMID: 34644110 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources